{"id":"adefovir-dipivoxil-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity / renal dysfunction"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Asthenia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL922","moleculeType":"Small molecule","molecularWeight":"501.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adefovir dipivoxil is a prodrug that is converted to adefovir in vivo. Adefovir acts as a nucleotide analog that inhibits hepatitis B virus (HBV) reverse transcriptase and DNA polymerase, thereby suppressing viral replication. It is effective against both wild-type HBV and lamivudine-resistant HBV strains.","oneSentence":"Adefovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:42.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"Lamivudine-resistant hepatitis B"}]},"trialDetails":[{"nctId":"NCT01300234","phase":"PHASE3","title":"Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-30","conditions":"Hepatitis B","enrollment":512},{"nctId":"NCT01353742","phase":"PHASE1","title":"Lamivudine and Adefovir Dipivoxil Fixed Dose Combination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-21","conditions":"Hepatitis B, Chronic","enrollment":40},{"nctId":"NCT00371761","phase":"PHASE3","title":"PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hepatitis B, Chronic (CHB)","enrollment":25},{"nctId":"NCT00116805","phase":"PHASE3","title":"A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-06","conditions":"Chronic Hepatitis B","enrollment":266},{"nctId":"NCT00117676","phase":"PHASE3","title":"A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-02","conditions":"Chronic Hepatitis B","enrollment":382},{"nctId":"NCT02598063","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Hepatitis B, Chronic","enrollment":255},{"nctId":"NCT00986778","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT02075294","phase":"","title":"Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Ying-Jie Ji","startDate":"2010-01","conditions":"Hepatitis B, Chronic","enrollment":242},{"nctId":"NCT00410202","phase":"PHASE3","title":"Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Hepatitis B, Chronic","enrollment":629},{"nctId":"NCT00001082","phase":"PHASE3","title":"The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1996-12","conditions":"Cytomegalovirus Infections, HIV Infections","enrollment":505},{"nctId":"NCT00095121","phase":"PHASE3","title":"Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-06","conditions":"Chronic Hepatitis B","enrollment":173},{"nctId":"NCT00307489","phase":"PHASE2","title":"Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-03","conditions":"Chronic Hepatitis B","enrollment":106},{"nctId":"NCT00376259","phase":"PHASE3","title":"Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hepatitis B","enrollment":43},{"nctId":"NCT00753467","phase":"PHASE2","title":"A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Huntington Medical Research Institutes","startDate":"2008-09","conditions":"Hepatitis B","enrollment":30},{"nctId":"NCT00324961","phase":"PHASE4","title":"Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Chronic Hepatitis B","enrollment":533},{"nctId":"NCT00441974","phase":"PHASE4","title":"Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Chronic Hepatitis B","enrollment":1470},{"nctId":"NCT00316719","phase":"PHASE3","title":"Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT00857675","phase":"PHASE3","title":"A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-12","conditions":"Chronic Hepatitis B","enrollment":480},{"nctId":"NCT00810524","phase":"PHASE4","title":"Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-01","conditions":"Hepatitis B, Chronic","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Adefovir Dipivoxil Tablets","genericName":"Adefovir Dipivoxil Tablets","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adefovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus. Used for Chronic hepatitis B infection, Lamivudine-resistant hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}